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Abstract
Aims/hypothesis A European Phase III trial of GAD formulated
with aluminium hydroxide (GAD-alum) failed to reach its prima-
ry endpoint (preservation of stimulated C-peptide secretion from
baseline to 15 months in type 1 diabetes patients), but subgroup
analysis showed a clinical effect when participants from Nordic
countries were excluded, raising concern as to whether the mass
vaccination of the Swedish and Finnish populations with the
Pandemrix influenza vaccine could have influenced the study
outcomes. In the current study, we aimed to assess whether
Pandemrix vaccination affects the specific immune responses
induced by GAD-alum and the C-peptide response.
Methods In this secondary analysis, we analysed data ac-
quired from the Swedish participants in the Phase III GAD-
alum trial who received subcutaneous GAD-alum vaccination
(two doses, n = 43; four doses, n = 46) or placebo (n = 48).
GAD autoantibodies (GADA) and H1N1 autoantibodies,
GAD65-induced cytokine secretion and change in fasting
and stimulated C-peptide levels from baseline to 15 months
were analysed with respect to the relative time between H1N1
vaccination and the first injection of GAD-alum.
Results GADA levels at 15 months were associated with the
relative time between GAD-alum and Pandemrix administration
in participants who received two doses of the GAD-alum vac-
cine (p = 0.015, r = 0.4). Both in participants treated with two
doses and four doses of GAD-alum, GADA levels were higher
when the relative time between vaccines was ≥210 days
(p < 0.05). In the group that received two doses of GAD-alum,
levels of several GAD65-induced cytokines were higher in par-
ticipants who received the H1N1 vaccination and the first GAD-
alum injection at least 150 days apart, and the change in fasting
and stimulated C-peptide at 15 months was associated with the
relative time between vaccines. Neither of these effects were
observed in individuals who received four doses of GAD-alum.
Conclusions/interpretation In individuals who received two
doses of GAD-alum, receiving the Pandemrix vaccine closer
to the first GAD-alum injection, i.e. <150 days, seemed to
affect both GAD65-induced immune response and C-peptide
preservation.
Trial registration: ClinicalTrials.gov NCT00723411.
Keywords Children . GAD . H1N1 . Immune intervention .
Type 1 diabetes . Vaccine
Abbreviations
GADA Glutamic acid decarboxylase autoantibodies
GAD-alum Glutamic acid decarboxylase formulated
with aluminium hydroxide
H1N1Ab H1N1-haemagglutinin antibody
PBMC Peripheral blood mononuclear cell
Th T helper
Introduction
Preservation of residual beta cell function in type 1 diabetes may
play an important role in an individual’s quality of life, avoidance
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of complications and even long-term survival [1], but most clin-
ical interventions to date in individuals with recent-onset type 1
diabetes have shown no or limited efficacy [2–8]. In a Phase II
trial (NCT00435981), GAD65 formulated with aluminium hy-
droxide (GAD-alum) showed efficacy in preserving residual in-
sulin secretion in children and adolescents with recent-onset type
1 diabetes [9, 10]. However, a subsequent Phase III trial of
GAD-alum (NCT00723411) failed to reach its primary outcome
[11], raising the question: why did efficacy differ from that seen
in the previous Phase II study? Indeed, in the Phase III GAD-
alum trial the treatment had significant efficacy in several
prespecified subgroups, such as participants from non-Nordic
countries, but not in Nordic participants, a group that was dom-
inated by Swedes. Prespecified exploratory analyses, including
analyses of genetic risk related to HLA genotypes, did not find
any associations explaining the different outcomes between
Nordic and non-Nordic participants [11].
A particular feature of the Swedish and Finnish participants
in the Phase III GAD-alum trial was that a vaccination cam-
paign against the influenza A (H1N1) virus began in both
countries in October 2009, following the WHO issuing a pan-
demic alert for the influenza strain A/(H1N1)pdm09. As a
consequence, most Swedish and Finnish participants in the
study had been vaccinatedwith Pandemrix, a vaccine that uses
the potent AS03 adjuvant containing α-tocopherol, a mole-
cule with a powerful immunomodulatory effect [12]. The abil-
ity for AS03 to promote innate immune system activation not
solely at the injection site but also in non-regional lymph
nodes, making it more potent than aluminium hydroxide in
terms of immune system activation, has previously been de-
scribed [13]. Indeed, AS03 has been associated with narcolep-
sy in Sweden and Finland [14]. Together, the Swedish and
Finnish participants constituted nearly half of the Phase III
GAD-alum study cohort (166/334 participants), raising con-
cerns as to whether Pandemrix vaccination was one of the
factors influencing the study outcome, possibly contributing
to the difference seen between the Nordic and non-Nordic
populations, with participants from the latter receiving another
kind of influenza vaccination [11].
Although it is well known that vaccines can interfere with
each other to decrease vaccination efficacy, the possible interfe-
rence of vaccinations with autoantigen treatment in type 1 dia-
betes is a poorly explored field. In the Phase III GAD-alum trial,
treatment with any vaccine within 1 month prior to the first
GAD-alum dose or planned vaccinations up to 2 months after
the last GAD-alum injection were not permitted, with the excep-
tion of influenza vaccination. We have previously shown that
GAD-alum has a specific immunomodulatory effect, indicated
by enhanced GAD autoantibodies (GADA) and specific in vitro
cytokine secretion upon GAD65 stimulation [15, 16]. Thus, in
the current study, we aimed to assess whether vaccination with
Pandemrix might have interfered with the specific immune and
C-peptide response to GAD-alum treatment.
Methods
Participants The design and characteristics of the Phase III
GAD-alum trial (NCT00723411) have been previously de-
scribed [11]. The study was a multicentre, randomised, double-
blinded trial performed in nine European countries (Finland,
France, Germany, Italy, the Netherlands, Slovenia, Spain,
Sweden and the UK). Individuals (n = 334) aged 10–20 years
with fasting C-peptide levels >0.1 nmol/l and detectable serum
GADAwere enrolled within 3 months of receiving a diagnosis
of type 1 diabetes. Participants received either: (1) four doses of
20 μg GAD-alum on days 1, 30, 90 and 270 (the ‘four-dose’
group); (2) two doses of GAD-alum on days 1 and 30, followed
by two doses of placebo on days 90 and 270 (the ‘two-dose’
group); or (3) four doses of placebo on days 1, 30, 90 and 270.
The study was approved by relevant regulatory authorities and
research ethics boards for the participating sites and countries.
Written consent and/or assent was acquired from all participants
and guardians, as required. Samples from 137 of the 148
Swedish participants in the Phase III GAD-alum trial were in-
cluded in the current study (Fig. 1).
H1N1 haemagglutinin antibodies Influenza A/H1N1
haemagglutinin antibodies (H1N1Abs) were detected with a
radiobinding assay, as described elsewhere [17]. Briefly, re-
combinant A/H1N1 haemagglutinin was labelled with 35S-
methionine (PerkinElmer Life and Analytical Sciences,
Brussels, Belgium). H1N1Abs were analysed, separating
bound antibody from free antigen with protein A-Sepharose
(Invitrogen, Carlsbad, CA, USA). The cut-off level for
H1N1Ab positivity was 71 RU/ml [17].
GADA, C-peptide and cytokine secretion In this secondary
analysis, GADA,C-peptide and cytokine secretionwere analysed
using data previously acquired for the Swedish participants in the
Phase III GAD-alum trial (n = 137), as described elsewhere [15].
Briefly, serum GADA titres were determined using a GAD65
antibody ELISA (RSR, Cardiff, UK) [18]. C-peptide analysis
was performed with an Immulite 2000 C-peptide kit on an
Immulite 2000 analyser (Siemens Healthcare Diagnostics
Product, Llanberis, UK). The clinical effect of treatment was
determined via changes in stimulated C-peptide secretion mea-
sured as AUC, reported as a percentage change from baseline.
For cytokine quantification, peripheral blood mononuclear
cells (PBMCs) were cultured for 7 days in the presence of
5 μg/ml recombinant human GAD65 (Diamyd Medical,
Stockholm, Sweden) or in medium alone at 37°C in 5% CO2,
as previously described [15, 16]. IL-1β, IL-2, IL-5, IL-10, IL-13,
IL-17, TNF-α and IFN-γ were measured in cell culture super-
natant fractions using a Bio-Plex Pro Cytokine Panel (Bio-Rad,
Hercules, CA, USA) according to the manufacturer’s instruc-
tions. Data were collected using the Luminex 200 (Luminex
xMAP; Luminex, Austin, TX, USA). The specific antigen-
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induced cytokine secretion level was calculated by subtracting
the spontaneous secretion (i.e. secretion fromPBMCs cultured in
medium alone) from the one following stimulation with GAD65.
Statistical analysisAs datasetswere significantly different from
a Gaussian distribution, as determined using the Kolmogorov–
Smirnov test, non-parametric tests corrected for ties were used.
Unpaired analyses for three or more groups were performed
using the Kruskal–Wallis test and correlations were analysed
using the Spearman’s rank correlation coefficient test.
Differences between groups were calculated using the Mann–
Whitney U test. A probability level of <0.05 was considered
statistically significant. Calculations were performed using IBM
SPSS Statistics version 23 (IMB SPSS, Armonk, NY, USA) and
graphical representations were developed using GraphPad Prism
5 for Windows (GraphPad Software, La Jolla, CA, USA).
Results
Samples from the Swedish participants of the GAD-alum
study were stratified according to treatment arm (two doses,
four doses or placebo) and further stratified by receipt of
H1N1 vaccination. Participants who received the H1N1 vac-
cine were classified as ‘close’ and ‘far’, defined by the time
between administration of the first injection of GAD-alum/
placebo and H1N1 vaccination (Fig. 1).
GADA and H1N1Ab titres and relative time between
vaccinations The analysis of H1N1Abs in serum samples
collected at baseline and at 3 and 15 months of the Phase III
GAD-alum trial showed, as expected, that antibodies against
H1N1 increased in participants who received the influenza
vaccine, with significant differences at 15 months between
those who were vaccinated and those who were not (Fig. 2a–
c). We have previously shown that GADA levels are induced
by both two and four doses of GAD-alum, but not by placebo
[15]. In the current study, the GADA titres at 15 months (the
main study period) did not differ significantly between partic-
ipants who did and did not receive the H1N1 vaccine in any of
the groups (electronic supplementary material [ESM] Fig. 1).
H1N1Ab titres at 15 months were associated with the rel-
ative time between the first injection of GAD-alum and H1N1
administration in the four-dose group (p = 0.001, r = 0.53), but
not in the two-dose group (Fig. 2d, e). The analysis of GADA
levels at 15 months showed an association of GADAwith the
relative time between GAD-alum and H1N1 injections in the
two-dose group (p = 0.015, r = 0.4; Fig. 2d). A similar rela-
tionship seemed to exist in the four-dose group, without being
statistically significant (Fig. 2e).
Because the exploratory analyses of the Phase III GAD-
alum results showed that removing individuals who received
an H1N1 vaccination within 150 days of the initial treatment
tended to improve the estimate of treatment ratio (i.e. treat-
ment effect on C-peptide preservation) [11], we used 150 days
as a cut-off point to define the relative time between injections
as ‘close’ (<150 days) or ‘far’ (≥150 days) from each other.
The analysis of GADA levels using this definition showed
that GADA did not differ between participants who received
vaccinations ‘far’ from compared with ‘close’ to GAD-alum
H1N1
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Fig. 1 Flow chart for the
Swedish participants in the Phase
III trial. From the original
Swedish cohort (n = 148),
individuals included in this study
(n = 137) were divided according
to GAD-alum treatment (two
doses and four doses) or placebo.
Individuals within each arm were
stratified according to whether
they received the H1N1
vaccination or not. They were
further categorised according to
two different cut-off periods for
time between H1N1 vaccination
and the first GAD-alum injection,
into ‘close’ (<150 or <210 days)
or ‘far’ (≥150 or ≥210 days)
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treatment in either group (Fig. 3a, b). Since relatively few
participants received the two vaccinations within 150 days
of each other, the use of a later cut-off point at 210 days for
defining ‘close’ and ‘far’ rendered groups that were more even
in number. The analysis using this cut-off revealed that
GADA levels were higher in participants receiving the
GAD-alum and H1N1 treatments more than 7 months apart
than in those who received them within 7 months, both in the
two-dose and four-dose groups (Fig. 3c, d).
Cytokine secretion and influenza vaccination Assessment
of PBMC cytokine secretion during the Phase III GAD-alum
study showed that GAD-alum treatment had a specific immu-
nomodulatory effect, as shown by in vitro GAD65-induced
cytokine secretion [15]. Comparison of GAD65-induced cyto-
kine levels at 15 months did not reveal any difference between
participants who did or did not receive the influenza vaccina-
tion (data not shown).
To determine whether the relative time between the vaccina-
tions and GAD-alum treatment had an impact on GAD65-in-
duced cytokine secretion, we compared cytokine levels between
participants who received the H1N1 vaccine ‘close’ to
(<150 days) and ‘far’ from (≥150 days) the first GAD-alum
injection. Within the two-dose group, we observed higher levels
of IL-13, IFN-γ and IL-17 in the ‘far’ vaccinated participants
compared with those vaccinated ‘close’ to GAD-alum treatment
(Fig. 3e). In addition, IL-5, IL-10 and IL-1β seemed to be in-
creased in the group who received H1N1 vaccinations ‘far’ from
GAD-alum treatment, although this did not reach statistical sig-
nificance (Fig. 3e).Analysis of cytokine levels using the 210days
cut-off to define ‘close’ and ‘far’ vaccinations in the two-dose
group revealed a similar pattern to that observed with the
150 days cut-off (Fig. 3f). In contrast to other cytokines, IL-2
was higher in the participants vaccinated ‘close’ to GAD-alum
treatment using both cut-off values (although this was only sig-
nificant using the 210 days cut-off). This is very interesting con-
sidering the lack of effect seen in the four-dose group, where no
differenceswere observed between participants who received the
vaccinations ‘close’ and ‘far’ fromGAD-alum treatment, regard-
less of which cut-off point was applied (ESM Table 1).
Cytokine profile and relative time between vaccinations
We have previously reported that the cytokine profile after
GAD-alum administration tends to switch from awide cytokine
profile towards a more predominant T helper (Th)2-associated
profile from baseline to 21 months [15]. Thus, we next exam-
ined the relative cytokine contribution to total GAD65-induced
cytokine secretion in participants who received H1N1 vaccina-
tion in relation to the relative time to the first GAD-alum injec-
tion. Using the 150 days cut-off period, we observed that par-
ticipants in the two-dose group who received the influenza and
GAD-alum injections ‘far’ apart displayed a more pronounced
Th2-associated profile than participants receiving them ‘close’
(Fig. 3g, h). No differences in the relative cytokine contribution
to total GAD65-induced cytokine secretion were detected in the
four-dose group (Fig. 3i, j).
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Fig. 2 (a–c) H1N1Ab titres at 15months in participants who received (a)
placebo, (b) two doses of GAD-alum or (c) four doses of GAD-alum.
Participants within each arm were stratified according to whether they
received H1N1 vaccination or not. Median values are indicated by hori-
zontal lines. (d, e) GADA (black circles) and H1N1Ab (white circles)
titres for each participant at 15 months and their correlation with the
relative time (days) between the first injection of GAD-alum and H1N1
vaccine in (d) the two-dose group (GADA, p = 0.015, r = 0.4; H1N1,
p = 0.079, r = 0.29) and (e) the four-dose group (GADA,
p = 0.16,r = 0.24; H1N1, p = 0.001, r = 0.53). *p < 0.05, **p < 0.01 vs
not vaccinated
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GADA and cytokine levels in ‘far’ vaccinated individuals
Correlation analysis of GADA levels at 15 months revealed
two distinct clusters of ‘far’ vaccinated participants in the two-
dose group using the 210 day cut-off, raising the question as to
whether they had some common phenotypic or immunologi-
cal features. A cut-off at 1200 U/ml for GADA seemed to
separate ‘far’ vaccinated participants into clusters with higher
and lower GADA levels, and was used to calculate cytokine
levels for the two subgroups. Interestingly, participants within
the group with high GADA titres seemed to also have higher
IL-13, IL-5, IL-17, TNF-α, IFN-γ, IL-10 and IL-1β levels
compared with participants with lower GADA titres, although
this data did not reach statistical significance (ESM Fig. 2).
Change in fasting C-peptide and AUC among H1N1-
vaccinated participants We next assessed whether there
was any association between the relative time between
GAD-alum and H1N1 injections and the change in fasting
and stimulated (AUC) C-peptide from baseline to 15 months.
Intriguingly, a positive correlation was observed between the
change in fasting C-peptide and the relative time between the
two treatments in the two-dose group (p = 0.029, r = 0.31), but
not in the four-dose group (p = 0.13, r = −0.19) (Fig. 4a, b).
No association was found between the change in AUC and the
relative time between treatments in either the two-dose or
four-dose group (ESM Fig. 3). Despite this association in
































































































































































































































































































































Fig. 3 (a–d) GADA levels at 15 months in the (a, c) two-dose and (b, d)
four-dose GAD-alum recipients who received the H1N1 vaccine.
Participants from both groups were divided according to the relative time
between influenza vaccination and the first GAD-alum injection to define
‘close’ (<150 and <210 days, circles) and ‘far’ (≥150 and ≥210 days,
squares) vaccinations. (e, f) Cytokine levels in H1N1-vaccinated partici-
pants from the two-dose group according to the ‘close’ (black bars) and
‘far’ (white bars) vaccination cut-off: (e) 150 days and (f) 210 days. (g–h)
Levels of antigen-induced cytokine secretion upon in vitro PBMC stim-
ulation with GAD65 are given after subtraction of spontaneous secretion.
IL-13, IL-5, IL-17, TNF-α, IFN-γ, IL-10, IL-1β and IL-2 were detected
using Luminex. Relative contribution (%) of each cytokine to the GAD65-
induced cytokine profile in (g, h) two-dose and (i, j) four-doseGAD-alum
recipients according to the 150 days cut-off are represented by pie charts.
For (a–e), data are presented as median values. *p < 0.05 and **p < 0.01,
‘close’ vs ‘far’ H1N1 vaccination
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loss of fasting C-peptide or AUC at 15 months between par-
ticipants who received the H1N1 vaccine and those who did
not (ESM Fig. 4). However, comparison of ‘close’ and ‘far’
vaccinated individuals, using both the 150 and 210 days cut-
off period, showed that ‘close’ vaccinated individuals within
the two-dose group had greater reduction in fasting and stim-
ulated C-peptide at 15 months compared with ‘far’ vaccinated
participants in the same group (Fig. 4c–f), although the reduc-
tion in stimulated C-peptide was non-significant using the
150 days cut-off value. No differences were observed between
‘close’ and ‘far’ vaccinated participants in the four-dose group
(ESM Fig. 5).
Discussion
In this study, we evaluated whether vaccination against the
H1N1 virus with the Pandemrix vaccine could have influenced
the specific immune response induced by GAD-alum treatment
and, if so, whether an effect was also seen in residual insulin
secretion. It was interesting to observe that GADA levels were
associated with the relative time between GAD-alum and
H1N1 injections in the two-dose group, and that GADA levels
were higher in participants who received the GAD-alum and
H1N1 injections more than 210 days apart, compared with
those who received them closer together. Consistent with the
GADA results, we also observed increased levels of several
GAD65-induced cytokines in participants within the two-dose
group who were given GAD-alum and H1N1 injections ‘far’
apart (≥210 days) compared with those who received them
‘close’ (<210 days). Intriguingly, participants within the two-
dose group who received GAD-alum and the H1N1 vaccine
‘far’ apart had, in parallel to higher GADA and GAD65-in-
duced cytokine levels, a significantly smaller decline in both
fasting and stimulated C-peptide, as compared with those vac-
cinated ‘close’ to GAD-alum treatment. Together, our findings
suggest that vaccination with Pandemrix within a certain time
frame with respect to the first GAD-alum injection seems to
interfere with both the specific immune response induced by
GAD65 and C-peptide preservation.
It is difficult to explain why the association between GADA
levels and the relative time between the GAD-alum and H1N1
injections, and the differences between ‘close’ and ‘far’ vacci-
nated individuals observed in the two-dose group were not
evident for the four-dose group. We have previously shown
that the small number of participants in the two-dose GAD-
alum group who completed the 30 months’ visit of the Phase
III GAD-alum trial had significantly less decline in both fasting
and stimulated C-peptide, and a significantly larger proportion
of these participants retained more than 25% of their initial C-
peptide, while C-peptide in the placebo and four-dose groups
continued to decline [19]. Results from the trial showed that a
predominant secretion of GAD65-induced proinflammatory cy-
tokines early after treatment was associated with low stimulated
C-peptide at 30months in participants from the two-dose group
[15]. Interestingly, in the current study, we found that the Th2
cytokines, IL-5 and IL-13, contributed to approximately 80%
of the cytokine profile of ‘far’ vaccinated participants in the
two-dose group using the 150 days cut-off, suggesting a stron-
ger Th2 deviation in the GAD65-specific immune response in
‘far’ vaccinated individuals.
Although the investigation of immune interference with
combined vaccination and the assessment of immune re-
sponses to vaccinations are important parts of vaccine devel-
opment, the possible interference of vaccines with autoantigen
treatment in type 1 diabetes is a poorly explored field.
According to our results, the reduced specific immune re-
sponse to GAD65 in individuals with a shorter relative time
between H1N1 and GAD-alum injections suggests that the
powerful immunomodulatory effect of the adjuvant AS03
used in the Pandemrix vaccine might have affected the specif-
ic immune response induced by GAD-alum.
Detection of differences in the immune response when pa-
tients vaccinated against H1N1 were compared as ‘close’ and
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Fig. 4 Change (Δ) in fasting C-peptide (baseline to 15 months) for each
participant and its correlation with the relative time (days) between the
first injection of GAD-alum and receipt of the H1N1 vaccine in the (a)
two-dose and (b) four-dose groups. Significant correlation in the two-
dose group was found betweenΔ fasting C-peptide and the relative time
between vaccinations (p = 0.029, r = 0.31). (c–f)Δ fasting and stimulated
(AUC) C-peptide in the two-dose group from baseline to 15 months in
H1N1-vaccinated participants. Cut-offs of 150 and 210 days between
H1N1 vaccination and GAD-alum treatment were used to define ‘close’
(<150 and <210 days, circles) and ‘far’ (≥150 and ≥210 days, squares)
vaccinations. For (c–d), data are presented as median values. *p < 0.05
and **p < 0.01, ‘close’ vs ‘far’ H1N1 vaccination
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‘far’ using relative periods longer than those accepted in the
Phase III trials for other vaccinations raises the question as to
whether the interference of other vaccines with autoantigen
administration might last longer than previously believed.
Of course, immune interference between treatments is not
always clinically important, but our observation of lower C-
peptide levels in participants with a diminished GAD65-induced
immune response is very interesting, and supports the hypothesis
that Pandemrix vaccination in Sweden and Finland may have
affected the outcome of the Phase III GAD-alum trial.
It has recently been suggested that the high immunogenic-
ity of H1N1 vaccines formulated with AS03 seems to be due
to the capacity of the adjuvant to both stimulate increased
activation of naive B cells, reducing immune interference with
previous vaccines, and increase the adaptation of pre-existing
memory B cells, giving improved specificity to the H1N1
vaccine [20]. Whether the effect observed by us is due to the
potency of this specific adjuvant used in Pandemrix, or to
mechanisms that may be relevant for other adjuvants or simul-
taneous vaccinations, should be addressed in future studies.
Different vaccines stimulate the immune system in different
ways, with some providing a stronger and broader response
than others, as determined by the nature and amount of anti-
gen, the route of administration and the adjuvant used.
Adjuvants impact the kinetics and magnitude of both T and
B cell responses to a given antigen. For instance, it has recent-
ly been reported that five different adjuvants formulated with
the same antigen induced different adaptive responses, with a
lower reactogenicity and lower magnitude of T and B cell
responses in the group where the antigen was alum-
formulated [21]. Low immunogenicity of alum-formulated
vaccines raises the question as to whether other vaccines
should be avoided close to GAD-alum immunotherapy. It is
important to note that, despite being an attractive therapeutic
modality for years, immunotherapy with autoantigens in type
1 diabetes has not been successfully translated into clinical
practice, supporting the importance of applying results and
experiences from previous trials into new clinical studies
and into the development of efficacious treatments.
There are some limitations to be considered in this study.
Because WHO had declared a pandemic alert for the influenza
A/(H1N1)pdm09 strain, very few participants enrolled in the
Phase III GAD-alum study declined to receive the influenza
vaccination at the time of the study. This resulted in a low
number of H1N1 non-vaccinated participants, a factor limiting
the statistical assessment between vaccinated and non-
vaccinated individuals within each GAD-alum treatment arm.
The same issue limited the analysis of the effect of the H1N1
vaccine given before or after the first injection of GAD-alum,
since this stratification led to very few individuals in the group
who received H1N1 before the first injection of GAD-alum.
It would also have been very interesting to be able to com-
pare the immune responses between Swedish participants and
those from other European countries but collection of PBMC
for immunological analysis was only performed in the
Swedish population during the Phase III trial. Further, it would
also have been relevant to analyse the specific cytokine profile
induced by H1N1 vaccination, but limited sample volume
precluded stimulation of PBMC with H1N1.
In conclusion, overall our results support the idea that
H1N1 vaccination might have had an impact on the outcome
of the Phase III GAD-alum trial. This impact was mainly seen
in participants from the two-dose GAD-alum treatment group,
where immunological and clinical variables seemed to be af-
fected by the relative time difference between H1N1 vaccina-
tion and GAD-alum treatment. Signs of possible vaccine in-
terference were observed far beyond the time period during
which concomitant vaccinations, excluding influenza, were
disallowed in the Phase III GAD-alum trial. This should be
taken into consideration in the design of future clinical trials of
autoantigen treatment.
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